Startups & VC
Life Biosciences Closes $80M Series D for Rejuvenation Therapy
Life Biosciences completed an $80 million Series D during the April 4–10 period to fund human trials of its aging-reversal therapeutic ER-100.
Primary sources · 1
Life Biosciences completed an $80 million Series D during the April 4–10 period to fund human trials of its aging-reversal therapeutic ER-100.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.